Patients with cancer are at higher risk of developing venous thromboembolism (VTE)
compared with the general population. This elevated risk is due to several risk factors and …

Direct oral anticoagulants (DOACs) have largely replaced vitamin K antagonists, mostly
warfarin, for the main indications for oral anticoagulation, prevention and treatment of …

Background Despite recent improvements in the treatment of cancer, little is known about
the long-term survival in patients with cancer and venous thromboembolism. We aimed to …

Background The optimal duration of anticoagulation in patients with active cancer and
venous thromboembolism (VTE) is unknown. Current clinical guidelines advocate …

Venous thromboembolism (VTE) is a major cause of both morbidity and mortality in patients
with cancer. Venous thromboembolism, which includes both deep vein thrombosis and …

Purpose The aim of this study was to describe the incidence of venous thromboembolism
(VTE) and major bleeding among hospitalized patients with hematologic malignancy …

Abstract Background Risk assessment models (RAMs) are relevant approaches to identify
cancer outpatients at high risk of venous thromboembolism (VTE). Among the proposed …

Venous thromboembolism (VTE) is a frequent and potentially fatal complication in patients
with cancer. During the initial period after the thromboembolic event, a patient receiving …

Given the existing uncertainty regarding the effectiveness and safety of switching from low-
molecular-weight heparin (LMWH) to direct oral anticoagulants (DOACs) in patients with …

Background There is scarce evidence on the effectiveness and safety of recommended-
dose direct acting oral anticoagulants (DOACs) in obese patients with venous …